+1 wesheadley
Peter Lederman in Second Bout With COVID-19
I saw on Facebook late last night that Mike Fremer told one of his Audio Friends that he heard from Peter Lederman of Soundsmith that he is suffering his second round with COVID. Peter said he has blood clots on his lungs. That is all the post said. Here is hoping that Peter pulls through with a full recovery.
- ...
- 502 posts total
theaudiotweak, "Glupson there are results in the Philippines now. Why dont you look?" I did. I looked and they are not worth much yet. The success they are claiming was 100% (without even accounting for other possible factors and very unclear what criteria "improvement" met). The sample size was.....one. If it were April 1st, you could think someone is joking. CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP) :: CytoDyn Inc. (CYDY) Having said all of that, I am keeping fingers crossed that it actually works as advertised. |
A previous trial with the FDA was for 2 doses, the manufacturer requested a trial with 4 doses. Now there is to be a redo...Makes me wonder why the FDA over ruled the people that designed the drug..Leronlimab. The power of this molecule is reported to be a potent drug in the fight against HIV and some types of cancer. Maybe big drug firms are frightened by this molecule and want to mute the company or buy it up so as to continue with their sales of wares which are less effective. I hope not... People are still very ill and many are still dying here and everywhere. The fight is not over yet. Tom https://www.yahoo.com/now/cytodyn-files-protocol-u-fda-100000695.html |
"CytoDyn believes four weeks of leronlimab treatment to be sufficient to calm the cytokine storm..." Four weeks of storm? Hmmmmm... It is not easy to find CD12 Trial results published. Company website does not seem to help it's own case by much either... "Amongst all patients in mITT, the primary endpoint (all-cause mortality at Day 28) was not statistically significant. When age adjustment was conducted, the primary endpoint was much closer to statistically significant value." "With the age adjustment analysis in all other major secondary endpoints, there was consistent numerical superiority over the placebo group, with some secondary endpoints approaching statistical significance." Ok, enough of Coronavirus. |
- 502 posts total